Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Psychopharmacology Bulletin|January 1, 1992
Reliability and clinical concepts underlying global judgments in dementia: implications for clinical researchF Dahlke, A Lohaus, H GutzmannArchives of Physical Medicine and Rehabilitation|August 1, 1989
Treating chronic hemiparesis with modified biofeedbackJ Wissel, G Ebersbach, L Gutjahr, et al.Neurology|December 12, 2001
Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MSL Kappos, C Polman, C Pozzilli, et al.Der Nervenarzt|May 20, 2004
[Health care costs of multiple sclerosis in Austria. Cross-sectional study including consideration of quality of life]U Ganzinger, C Badelt, K Vass, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 27, 2014
Relapses in patients treated with fingolimod after previous exposure to natalizumabG Comi, R Gold, F Dahlke, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 21, 2003
Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized studyC Polman, F Barkhof, L Kappos, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 1, 1995
Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trialC H Polman, F Dahlke, A J Thompson, et al.Poultry Science|January 16, 2016
Effects of different limestone particle sizes in the diet of broiler breeders post molting on their performance, egg quality, incubation results, and pre-starter performance of their progenyI J M Bueno, D Surek, C Rocha, et al.Neurology|November 24, 2004
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trialsL Kappos, B Weinshenker, C Pozzilli, et al.Neurology|January 15, 2003
Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1bC Polman, L Kappos, R White, et al.Pageof 2